The polymerase (pol) coding sequence was determined for 40 independent clinical
cytomegalovirus isolates sensitive to ganciclovir and foscarnet. Sequence alignments …

Human cytomegalovirus remains an important pathogen for transplant recipients. To date, a
limited number of drugs have been licensed for the treatment of HCMV infection and …

Mutations in both the viral phosphotransferase gene, UL97, and the DNA polymerase gene,
UL54, have been shown to confer ganciclovir resistance to cytomegalovirus (CMV) …

Technical advancements can enhance the accurate and timely genotypic detection of drug
resistance. Antivirals undergoing clinical trial offer the prospect of new viral targets and drug …

BACKGROUND: The cytomegalovirus (CMV) UL97 inhibitor drug maribavir (MBV) is
undergoing clinical antiviral trials. OBJECTIVES: To assess the MBV sensitivity of CMV …

Despite advances in preventive strategies, cytomegalovirus (CMV) infection remains a major
complication in solid organ and hematopoietic cell transplant recipients. CMV infection may …

Letermovir is a human cytomegalovirus (CMV) terminase inhibitor recently approved as
prophylaxis in stem cell transplant recipients. In further studies of emerging drug resistance …

Cytomegalovirus infections are associated with severe morbidity and mortality is patients at
risk for disease because of immune system disabilities; in particular, recipients of stem cell …

Objectives Cytomegalovirus (CMV) drug resistance is a therapeutic challenge in the
transplant setting. No longitudinal cohort studies of CMV resistance in a real-life setting have …

Most ganciclovir (GCV)–resistant cytomegalovirus (CMV) isolates contain UL97 gene
mutations at codon 460 or 520 or between codons 590 and 607, where an increasing variety …